000			02012 a2200589 4500
005			20250514015053.0
264		0	_c20011228
008			200112s 0 0 eng d
022			_a0030-2414
024	7		_a10.1159/000055399 _2doi
040			_aNLM _beng _cNLM
100	1		_aLeyland-Jones, B
245	0	0	_aDose scheduling--Herceptin. _h[electronic resource]
260			_bOncology _c2001
300			_a31-6 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAbdominal Muscles
650	0	4	_aAnimals
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aArea Under Curve
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aCapecitabine
650	0	4	_aCisplatin _xadministration & dosage
650	0	4	_aClinical Trials, Phase I as Topic
650	0	4	_aClinical Trials, Phase II as Topic
650	0	4	_aDeoxycytidine _xadministration & dosage
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Antagonism
650	0	4	_aDrug Evaluation, Preclinical
650	0	4	_aDrug Synergism
650	0	4	_aFeasibility Studies
650	0	4	_aFemale
650	0	4	_aFluorouracil _xadministration & dosage
650	0	4	_aHalf-Life
650	0	4	_aHaplorhini
650	0	4	_aHumans
650	0	4	_aInfusions, Intravenous
650	0	4	_aInjections, Subcutaneous
650	0	4	_aMethotrexate _xadministration & dosage
650	0	4	_aNeoplasm Metastasis
650	0	4	_aPaclitaxel _xadministration & dosage
650	0	4	_aSafety
650	0	4	_aTrastuzumab
650	0	4	_aTreatment Outcome
650	0	4	_aVinblastine _xadministration & dosage
650	0	4	_aXenograft Model Antitumor Assays
773	0		_tOncology _gvol. 61 Suppl 2 _gp. 31-6
856	4	0	_uhttps://doi.org/10.1159/000055399 _zAvailable from publisher's website
999			_c11610382 _d11610382